SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Q/C TECHNOLOGIES, INC.
Date: Jan. 28, 2026 · CIK: 0001321834 · Accession: 0000000000-26-001037

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

Date
January 28, 2026
Author
Joshua Silverman
Form
UPLOAD
Company
Q/C TECHNOLOGIES, INC.

Letter

January 28, 2026 Joshua Silverman Executive Chairman Q/C Technologies, Inc. 1185 Avenue of the Americas, Suite 249 New York, NY 10036 Re:Q/C Technologies, Inc. Draft Registration Statement on Form S-3 Submitted January 23, 2026 CIK No. 0001321834 Dear Joshua Silverman: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement and non-public draft submission on EDGAR at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Rick Werner, Esq.

Show Raw Text
January 28, 2026
Joshua Silverman
Executive Chairman
Q/C Technologies, Inc.
1185 Avenue of the Americas, Suite 249
New York, NY 10036
Re:Q/C Technologies, Inc.
Draft Registration Statement on Form S-3
Submitted January 23, 2026
CIK No. 0001321834
Dear Joshua Silverman:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement and non-public draft
submission on EDGAR at least two business days prior to the requested effective date and time.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the
company and its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Rick Werner, Esq.